Please login to the form below

Not currently logged in
Email:
Password:

autoimmune conditions

This page shows the latest autoimmune conditions news and features for those working in and with pharma, biotech and healthcare.

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Today’s decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029; nonetheless we remain committed to providing important treatment ... Enbrel, which yielded

Latest news

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • How early-stage clinical research is facilitating the new wave of personalised medicines How early-stage clinical research is facilitating the new wave of personalised medicines

    is also being used to treat autoimmune and cardiac conditions, and biologic medicines, which now account for 15% of medicines prescribed in Japan and 30% in the USA (in 2018). ... as the technology is tested in more conditions and biomarkers.

  • Piloting a route to the biosimilars opportunities in Europe Piloting a route to the biosimilars opportunities in Europe

    Biological medicines represent a major advance in the treatment of serious pathological conditions such as cancer,  neurodegenerative and autoimmune diseases, in the form of biosimilars.

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... The latter is a vital service for patients with chronic

  • Taking a lean and careful approach Taking a lean and careful approach

    This fits well with our mission to tackle unmet needs. Autoimmune conditions are increasing and diabetes is at epidemic levels. ... A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
...
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...